| NCT07123103 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2025-08-18 | 2028-02 | 2027-11 |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | RECRUITING | PHASE2, PHASE3 | 2025-07-21 | 2029-06 | 2029-06 |
| NCT06962332 | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) | RECRUITING | PHASE1 | 2025-05-13 | 2026-04 | 2025-12 |
| NCT06952010 | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2025-05-01 | 2027-11 | 2027-05 |
| NCT06630247 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | TERMINATED | PHASE1 | 2024-10-17 | 2025-05-07 | 2025-05-07 |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | RECRUITING | PHASE1 | 2024-08-06 | 2027-10-20 | 2026-11-23 |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2024-06-07 | 2029-03 | 2028-08 |
| NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-04-03 | 2029-08-03 | 2029-01-03 |
| NCT06191796 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | TERMINATED | PHASE1 | 2024-01-25 | 2025-05-12 | 2025-05-12 |
| NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-01-01 | 2028-06 | 2025-07 |
| NCT05425940 | Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-09-07 | 2026-02 | 2025-08 |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | TERMINATED | PHASE1 | 2022-04-12 | 2022-11-01 | 2022-11-01 |
| NCT05176483 | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-12-14 | 2030-06-28 | 2030-06-28 |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | COMPLETED | PHASE1 | 2021-06-07 | 2025-03-10 | 2025-03-10 |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | TERMINATED | PHASE1 | 2021-02-10 | 2024-05-02 | 2024-05-02 |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-06-30 | 2026-10-16 | 2024-04-19 |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-06-25 | 2027-01-31 | 2022-01-31 |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-03-20 | 2027-05-31 | 2026-08-31 |
| NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-10-05 | 2026-07-31 | 2020-08-19 |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-06-10 | 2024-12-01 | 2021-03-08 |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2017-09-05 | 2027-09-30 | 2023-02-21 |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | PHASE4 | 2015-02-25 | 2035-01 | 2020-07-15 |
| NCT01995058 | Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | TERMINATED | PHASE2 | 2013-12 | 2014-11 | 2014-11 |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | COMPLETED | PHASE3 | 2013-09-26 | 2021-01-12 | 2017-10-16 |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | COMPLETED | PHASE3 | 2013-06 | 2021-01-15 | 2015-05-22 |
| NCT01761773 | A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function | COMPLETED | PHASE1 | 2012-12 | 2014-07 | 2013-04 |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | COMPLETED | PHASE3 | 2012-07 | 2015-03 | 2014-09 |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | TERMINATED | PHASE3 | 2012-03 | 2015-01-13 | 2014-10 |
| NCT01493869 | Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects | COMPLETED | PHASE1 | 2011-09 | 2014-08 | 2014-05 |
| NCT01553656 | Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer | COMPLETED | PHASE1 | 2011-02 | 2015-07 | 2015-05 |
| NCT01068782 | Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse | COMPLETED | PHASE2 | 2010-04 | 2013-10 | 2011-05 |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2010-04 | | 2012-08 |
| NCT00940225 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | COMPLETED | PHASE2 | 2009-09 | 2014-06 | 2013-05 |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | COMPLETED | PHASE1 | 2009-09 | 2013-10 | 2012-11 |
| NCT00796484 | Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors | TERMINATED | PHASE1 | 2008-11 | 2010-11 | 2010-11 |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | COMPLETED | PHASE3 | 2008-06 | 2020-09 | 2011-10 |
| NCT00704392 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors | WITHDRAWN | PHASE1 | 2008-06 | 2009-12 | 2009-12 |
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | COMPLETED | PHASE2 | 2008-05 | 2012-12 | 2012-06 |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | TERMINATED | PHASE1 | 2007-12 | 2009-02 | 2009-02 |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer | COMPLETED | PHASE1, PHASE2 | 2007-12 | | 2012-08 |
| NCT00570635 | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | COMPLETED | PHASE2 | 2007-12 | 2009-05 | 2009-05 |
| NCT00526838 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | TERMINATED | PHASE1 | 2007-09 | 2010-12 | 2010-12 |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | TERMINATED | PHASE1 | 2007-08 | | |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | TERMINATED | PHASE1 | 2007-05 | 2011-04 | 2010-12 |
| NCT00475917 | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies | TERMINATED | PHASE1 | 2007-05 | 2008-12 | 2008-12 |
| NCT00460278 | Study of XL418 in Adults With Solid Tumors | SUSPENDED | PHASE1 | 2007-04 | | |
| NCT00451880 | Study of XL281 in Adults With Solid Tumors | COMPLETED | PHASE1 | 2007-02 | 2011-10 | 2011-10 |
| NCT00350831 | Study of XL820 Given Orally Daily to Subjects With Solid Tumors | COMPLETED | PHASE1 | 2006-07 | | |
| NCT00215605 | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | COMPLETED | PHASE1 | 2005-09 | 2012-07 | 2011-04 |
| NCT00129571 | Study of XL820 in Adults With Solid Tumors | COMPLETED | PHASE1 | 2005-08 | | |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | TERMINATED | PHASE1 | | | |